Obesity White Papers & Case Studies

  1. Helping To Bring Hematologic Oncology Therapies To Cancer Patients 11/17/2025

    Our mission is grounded in urgency and purpose: to shorten the time it takes for innovative blood cancer treatments to reach the patients and families who cannot afford to wait.

  2. Early-Phase Oncology Research Expertise 11/17/2025

    Our priority is guiding promising therapies to proof-of-concept with precision and urgency, because every day saved in development matters profoundly to patients living with cancer.

  3. Smarter Oversight, Earlier Action 11/17/2025

    When risk-based oversight is reduced to a compliance checkbox, critical signals can be missed and escalate into systemic issues.

  4. Rescuing Data Integrity: A Swift Transition And Quality Transformation 11/14/2025

    Uncover how this collaboration supported timely progress toward key study milestones, enabling smoother execution and more dependable output across data management and statistical activities.

  5. Quantitative ROI With DCTs 11/13/2025

    Through dedicated staffing, operational oversight, and collaboration with site teams, see how we were able to transform a struggling cardiology study into a revitalized recruitment effort.

  6. The True ROI Of Decentralized Clinical Trials 11/13/2025

    Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.

  7. Retention Begins With Recruiting The Right-Fit Patients 11/13/2025

    Recruiting the right patients into a clinical trial is only half the battle. To combat attrition, sponsors must also institute measures that ensure patients remain comfortable and confident throughout the trial.

  8. How AI Is Setting A New Standard In Clinical Development 11/13/2025

    Learn how to adopt artificial intelligence in practical, measurable ways, from protocol feasibility and cohort modeling to clinical trial disclosure and transparency.

  9. 4 New Approvals In Q3 Across Gene, Cell, RNA Therapies 11/13/2025

    Q3 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals. While regulatory progress continued, clinical development activity slowed.

  10. Your Partner For Simplified Site Operations And Maximized Returns 11/13/2025

    With dedicated CTA Negotiation, Site Payment, and Financial Analysis experts, we reduce site burden and optimize study execution so your team can focus on delivering exceptional research as care.